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The most frequent significantly altered gene identified in
this study was CDH1 in which loss-of-function mutations
occurred in 65% of cases and loss of heterozygosity or deletion
was identified in 94% of patients. These findings are consistent
with other studies and underscore the role of E-cadherin loss in
contributing to the characteristic discohesive morphology
associated with ILC.3
Given that the majority of ILCs are hormone receptor positive,
endocrine therapy is key to treatment. ILC appears to derive
particular benefit from treatment with aromatase inhibitors
compared with tamoxifen, which is possibly related to relative
tamoxifen resistance.18,19 The current study and TCGA analysis3
identified alterations that affect ER signaling, including muta-
tions in ER modulators that could lead to altered or divergent
ER-mediated signaling. Of note, the authors found that focal copy
number gains at 6q25.1, including ESR1, occur in 25% of lobular
tumors and that copy number changes corresponded to increased
expression of an ESR1mRNA gene expression signature. Although
TCGA analysis did not indicate copy number gain as significantly
enriched in ILC, it revealed increased ER activity in the form of
significantly higher levels of total and phosphorylated ER protein.
Beyond ESR1 and ER expression, ILC-specific mutations that af-
fect ER cofactors were identified. In both TCGA and the current
study, ILC was characterized by an increased incidence of FOXA1
mutations, whereas IDC was enriched for GATA3 mutations.
Similarly, lower GATA3 mRNA and protein expression in ILC and
reduced methylation at ER promoters were observed in the TCGA
cohort.3 Because both GATA3 and FOXA1 modulate ER tran-
scriptional activity, the results suggest preferential binding of ER
to FOXA1-bound promoter sites in ILC and to GATA3-bound
sites in IDC, which could lead to differential ESR1-regulated gene
expression.3,20 Both altered ER protein expression and unique mutation
patterns in ER transcription complex family members can affect
response to endocrine therapy.
Beyond CDH1 and ER signaling, 50% of ILCs harbor mu-
tations in one of three key genes that regulate the phosphatidy-
linositol 3-kinase (PI3K) pathway. Specifically, Desmedt et al2
identified an increased frequency of lobular-specific mutations in
PIK3CA, the PI3K-negative regulator PTEN, and the downstream
kinase AKT1. An increased incidence of PTEN loss-of-function
mutations or loss of heterozygosity as well as a high frequency of
Invasive lobular carcinoma (ILC) accounts for up to 15% of 
all invasive breast cancers.1 We have long recognized the unique 
clinical characteristics of ILC, but an increased understanding of its 
biology in contrast with the more common breast cancer histologic 
type, infiltrating ductal carcinoma (IDC), has emerged. The article 
that accompanies this editorial by Desmedt et al2 reinforces and 
extends this understanding.
ILC is characterized by loss of normal cell-cell adhesion, which 
results in discohesive cells that fail to form glandular structures. 
The defining genetic feature that distinguishes ILC from IDC is 
CDH1 mutation or loss of either mRNA or protein expression of 
the cell adhesion molecule E-cadherin; 95% of ILCs demonstrate 
some form of E-cadherin alteration.3,4 Most ILCs are of the 
classical histologic type, which is low grade and possesses a low to 
intermediate mitotic index,1 whereas less common ILC variants, 
such as the solid and mixed nonclassical types, often are high grade 
and associated with a poorer outcome than classical ILC.5 ILC of all 
types usually expresses estrogen receptors (ERs) and progesterone 
receptors and are rarely clinically human epidermal growth factor 
receptor 2 (HER2) positive. Perhaps related to CDH1 loss, which in 
other tumor types confers increased risk of invasion and metastasis,6,7 
some studies have suggested that patients with ILC have similar or 
worse long-term outcomes compared with patients with stage-
matched IDC.8,9 Metastatic ILC also has unusual patterns of spread 
to sites such as the ovaries, lining of the GI tract, and peritoneum.1,8 All 
these features are consistent with a unique biology.
Despite many studies that investigated the genomic and 
mutational landscape of breast cancer, lobular breast tumors have 
been largely underrepresented.4,10 Several studies have examined 
transcriptional profile differences that distinguish ILC from IDC; 
however, with the exception of the loss of CDH1 expression, few 
ILC-distinguishing features have been identified.11-16 Desmedt 
et al2 genomically profiled the largest cohort of primary invasive 
lobular breast tumors analyzed to date, which included 430 tumors 
analyzed for mutations and 170 for copy number aberrations, to 
identify and characterize the recurrent genomic alterations present 
in these tumors. The results of this large study in conjunction with 
remarkably consistent findings from 127 ILCs and 490 IDCs in The 
Cancer Genome Atlas (TCGA) project3 and 144 ILCs from a 
European cohort17 have clear biologic and clinical implications 
with regard to genetic alterations that drive lobular breast cancer.
PIK3CAmutations in ILC was observed in the TCGA and European
studies.3,17 In TCGA, loss or mutation of PTEN corresponded with
decreased PTEN protein expression and a concomitant increase in
activated or phosphorylated Akt protein expression in lobular
tumors. In fact, the levels of phosphorylated Akt protein expression
identified in lobular tumors was comparable to the expression of
these proteins in basal-like or HER2-enriched ductal tumors, which
have been shown to have the highest levels of PI3K/Akt signaling
among IDC tumors.4 Beyond protein expression, integrative analysis
of TCGA genomic data identified multiple alterations that con-
tribute to aberrant Akt/mammalian target of rapamycin signaling in
45% of ILC cases. Previous studies have linked loss of E-cadherin
with Akt activation and epidermal growth factor receptor (EGFR)
expression. Results fromTCGA that demonstrated overexpression of
phosphorylated EGFR in conjunction with data that describe the
increased incidence of PI3K/Akt pathway mutations from both the
current study and TCGA suggest that the ILC tumor environment
provides a favorable cellular context for altered Akt signaling3,4,21,22
and that the targeting of the PI3K/Akt pathway may be particularly
relevant in ILC.
The study by Desmedt et al2 is the first to characterize HER2
and HER3 mutations in ILC. Overall, 14% of ILC tumors were
either HER2 amplified or carried a mutation in HER2 or HER3.
These data suggest that ILC has the highest incidence of HER2-
mutated, nonamplified tumors among all breast cancer subsets. In
the TCGA study, 10% of ILCs had amplified or mutatedHER2, and
reverse phase protein assays revealed increased EGFR activity in
ILC. Together, these studies suggest that ERBB family signaling may
significantly contribute to ILC biology. Additional analyses are
necessary to fully illuminate the context and extent of alterations
that affect this family of genes as well as to understand the clinical
relevance of these alterations.
In the TCGA and European studies,3,17 transcriptome analyses
found at least two molecularly distinct subsets of ILC, including an
immune-related subset that appeared to have both high expression
of lymphocyte signaling pathway components and negative immune
response regulators. This finding may have consequences for the use
of immune checkpoint inhibitors or other immune-based approaches
in ILC.
Desmedt et al,2 in concert with similar initiatives published
within the past few months,3 have extensively characterized the
genomic landscape of ILC and have produced remarkably
consistent results that identify at least three significantly altered
and therapeutically relevant pathways. These are an important
first step to understanding ILC as well as the potential treatment
implications of this unique biologic subset of breast cancer. It is
now clear that ILC and IDC are distinct molecular diseases, a
fact that should be considered in future experimental and
therapeutic initiatives.
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